One potential target is Group B streptococcus, the most common cause of life-threatening infections in newborns.

BBC: Whooping cough vaccine a 'no-brainer' during pregnancy

Recently, Cepheid got 510(k) clearance from the U.S. Food and Drug Administration (a pre-marketing submission to demonstrate that the device to be marketed is safe and effective) for GeneXpert to work on Group B Streptococcus.

FORBES: Nanotech Takes On Homeland Terror